SHANGHAI, Jan. 29, 2024 /PRNewswire/ — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the…

SHANGHAI, Jan. 29, 2024 /PRNewswire/ — Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the…

NEW YORK, Jan. 29, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Lovesac Company (NASDAQ: LOVE) between March 30, 2023 and August 16, 2023, both dates inclusive (the “Class Period”), of the important February 20, 2024…

NEW YORK, Jan. 29, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of The Lovesac Company (NASDAQ: LOVE) between March 30, 2023 and August 16, 2023, both dates inclusive (the “Class Period”), of the important February 20, 2024…

NEW YORK, Jan. 29, 2024 /PRNewswire/ — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of VNET Group, Inc. (NASDAQ: VNET) between April 8, 2022 and February 15, 2023, both dates inclusive (the “Class Period”), of the important February 26, 2024…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.